Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structure-based drug design

P M Colman1

  • 1Biomolecular Research Institute, Parkville, Australia.

Current Opinion in Structural Biology
|December 1, 1994
PubMed
Summary
This summary is machine-generated.

Designing new drug ligands using protein structures is common, but many fail due to toxicity or poor bioavailability. Recent protein structure discoveries offer new therapeutic potential despite these challenges.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Crystal structure of Bax bound to the BH3 peptide of Bim identifies important contacts for interaction.

Cell death & disease·2015
Same author

Variola virus F1L is a Bcl-2-like protein that unlike its vaccinia virus counterpart inhibits apoptosis independent of Bim.

Cell death & disease·2015
Same author

How antibodies recognize virus proteins.

Immunology today·2014
Same author

Bax activation by Bim?

Cell death and differentiation·2009
Same author

EGL-1 BH3 mutants reveal the importance of protein levels and target affinity for cell-killing potency.

Cell death and differentiation·2008
Same author

Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands.

Cell death and differentiation·2008
Same journal

Tomogram exploration through template matching and deep learning.

Current opinion in structural biology·2026
Same journal

A comparative review of cryo-electron ptychography: Biological applications and future perspectives.

Current opinion in structural biology·2026
Same journal

Metabolic disruptions through a three-dimensional genomic lens.

Current opinion in structural biology·2026
Same journal

Collective variable design for biomolecular conformational dynamics.

Current opinion in structural biology·2026
Same journal

Polymer scaling in protein crowding: From dilute coils to semidilute meshes.

Current opinion in structural biology·2026
Same journal

Tuning the physicochemical properties of rationally designed protein-based biomolecular condensates.

Current opinion in structural biology·2026
See all related articles

Area of Science:

  • Drug discovery and development
  • Structural biology
  • Medicinal chemistry

Background:

  • Knowledge of target protein structures enables the design of novel ligands.
  • Many designed ligands exhibit poor drug-like properties, including toxicity, instability, and low bioavailability.
  • Recent advancements include the structural elucidation of numerous therapeutic protein targets.

Purpose of the Study:

  • To highlight the successes and limitations in structure-based ligand design.
  • To underscore the importance of protein structure determination in drug discovery.
  • To identify emerging therapeutic targets based on recent structural data.

Main Methods:

  • Review of recent literature on structure-based drug design.
  • Analysis of common challenges in ligand development (toxicity, stability, bioavailability).

Related Experiment Videos

  • Identification and categorization of newly characterized protein structures with therapeutic relevance.

    • Main Results:

    • Numerous examples of successful structure-based ligand design exist.
    • Significant challenges remain in translating designed ligands into viable drug candidates.
    • A growing number of protein structures, relevant for existing drugs or novel therapies, have been determined.

    Conclusions:

    • Structure-based design is a powerful tool, but drug-like properties require careful consideration.
    • Overcoming toxicity and bioavailability issues is critical for clinical success.
    • Newly identified protein structures present significant opportunities for future therapeutic interventions.